Diabetes Mellitus Type 2 Clinical Trial
Official title:
Observational Retrospective Multicenter Study to Evaluate Clinical Outcome Variables Change With dapaGLiflozin Treatment Introduced in Patients With T2D uncOntrolled by the Current Therapy in Real Clinical Practice in RussIA
The study will retrospectively collect clinical variables and socio-demographic data from
medical records of patients with T2DM initiating treatment with dapagliflozin after the
previous failure/inefficiency of other treatment options (defined as non-achievement of
target Hb1Ac) and according to the officially approved indication as per instruction for the
use of medicinal product.
It is expected that the best available data regarding clinical variables and patient
socio-demographic profiled will be collected from the patient medical records at up to 40
major Russian outpatient clinics/centers specialized in the treatment and management of T2DM
patients.
There are 2 time points:
- Baseline data: baseline data are defined as data available within 3 months prior to the
first dose of dapagliflozin. In case of presence of multiple data values within baseline
period the most recent pre-dose value will be selected
- Follow-up data: any post-baseline data will be considered as follow-up but the primary
analysis will be focused on data available at 6 plus/minus 3 months after the initiation
of dapagliflozin. In case of discontinuation dapagliflozin, data will be collected at
routine visit within 3-month time frame after the last dose
Objectives and Hypotheses:
Primary objective:
To describe HbA1c (glycosylated haemoglobin) change from baseline to follow-up
Secondary objectives:
Clinical data:
- To estimate percentage (%) of patients with reduction of HbA1c by 0.5% or more from
baseline to follow-up
- To estimate percentage (%) of patients reaching the therapeutic glycemic response (HbA1c
<7.0%) from baseline to follow-up
- To describe change of fasting blood glucose from baseline to follow-up
- To estimate change of body weight from baseline to follow-up
- To estimate percentage (%) of patients with body weight reduction by at least 5% from
baseline to follow-up
- To estimate percentage (%) of patients with reduction of HbA1c by 0.5% or more and body
weight reduction by at least 5% from baseline to follow-up
- To describe change of systolic and diastolic blood pressure from baseline to follow-up
(systolic and diastolic, in mmHg)
Methods:
Study design:
The study will retrospectively collect clinical variables and socio-demographic data from
medical records of patients with T2DM initiating treatment with dapagliflozin after the
previous failure/inefficiency of other treatment options (defined as non-achievement of
target Hb1Ac) and according to the officially approved indication as per instruction for the
use of medicinal product.
It is expected that the best available data regarding clinical variables and patient
socio-demographic profiled will be collected from the patient medical records at up to 40
major Russian outpatient clinics/centers specialized in the treatment and management of T2DM
patients.
There are 2 time points:
- Baseline data: baseline data are defined as data available within 3 months prior to the
first dose of dapagliflozin. In case of presence of multiple data values within baseline
period the most recent pre-dose value will be selected
- Follow-up data: any post-baseline data will be considered as follow-up but the primary
analysis will be focused on data available at 6 plus/minus 3 months after the initiation
of dapagliflozin. In case of discontinuation dapagliflozin, data will be collected at
routine visit within 3-month time frame after the last dose.
Data Source(s):
Participating investigators should be physicians-endocrinologists working in approximately 12
outpatient clinics specialized in management of patients with T2DM in Moscow. There is no
current legislation on EMR in Russia, so, paper medical records will be utilized, and data
collection using electronic CRFs will be done.
Study Population:
T2DM patients previously uncontrolled on standard therapy (mono-, double therapy with OADs:
metformin, SU or DPP-4 inhibitors or on insulin) initiating treatment with dapagliflozin as
monotherapy, combination with OADs or as add-on to insulin with available data on Hb1c within
3 months prior to the first dose of dapagliflozin. All consecutive patients at the clinic in
inclusion period who meet inclusion and exclusion criteria will be included.
Exposure(s):
Only patients initiating treatment with dapagliflozin as monotherapy, combination with OADs
or as add-on to insulin will be included in the study.
Outcome(s):
Population parameters
- Date of birth
- Gender
- Level of education
- Level of income
- Ethnicity/race
- Living conditions
- Working conditions All documented macro- and microvascular T2DM complications and
concomitant medications (antidiabetic drugs, statins, ACE inhibitors, sartans,
beta-blockers, calcium channel antagonists) will be collected for whole course of
dapagliflozin administration.
Clinical parameters
- Hb1Ac
- Fasting glucose
- Body weight
- Blood pressure (systolic and diastolic)
Sample Size Estimations:
Approximate sample size is 850 patients.
Statistical Analysis:
Epidemiological methods mainly will be used to represent the study data. A descriptive
analysis approach will be used to analyse study objectives. Descriptive statistics will be
used to analyse the study population, baseline data and clinical outcomes. The descriptive
statistics will include mean, standard deviation, median, minimum and maximum, range, number
of valid cases for continuous variables, number, percentage, and distribution for categorical
variables. The percentage will be given with the relevant two-sided 95% confidence intervals.
Only available data will be analyzed; no missing values imputation will be applied. Only
patients with available data on HbA1c both within 3 months prior to the first dose of
dapagliflozin and at 6±3 months after the initiation of dapagliflozin will be included in the
main analysis.
All other baseline, effectiveness parameters will be tabulated, assessed in subgroups where
available..
In order to evaluate the association between achievement of the HbA1C goals and patient
characteristics, the multivariate logistic regression model was developed. A binary
categorical attribute-HbA1C within/outside < 7% at 6±3 months after the initiation of
dapagliflozin -serves as a dependable variable in this model
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01267448 -
Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia
|
Phase 4 | |
Active, not recruiting |
NCT05330247 -
Cut Down on Carbohydrate in the Dietary Therapy of Type 2 Diabetes - The Meal Box Study
|
N/A | |
Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 | |
Terminated |
NCT02373865 -
Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT01741181 -
Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2
|
Phase 4 | |
Completed |
NCT01305434 -
Mulberry Leaf Extract and Blood Glucose Control in Diabetics
|
Phase 1/Phase 2 | |
Completed |
NCT01330121 -
Bridging the Gap by Transitional Care
|
N/A | |
Recruiting |
NCT00992797 -
Diabetes Intervention Trial With Vitamin D in Subjects of Nordic and Sub-Indian Ethnicity
|
Phase 2 | |
Completed |
NCT01580904 -
Impact of Pharmaceutical Care in Diabetics Patients
|
N/A | |
Active, not recruiting |
NCT00728403 -
Metabolic and Therapeutic Effects of American and Korean Red Ginseng in the Treatment of Type 2 Diabetes
|
Phase 2 | |
Completed |
NCT00763815 -
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone
|
Phase 3 | |
Active, not recruiting |
NCT00529815 -
Continuous Glucose Monitoring in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT00517465 -
A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.
|
Phase 1 | |
Completed |
NCT00119041 -
Diabetes Telemedicine Consultation: A Systems Improvement Intervention
|
N/A | |
Withdrawn |
NCT00417716 -
Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema
|
Phase 3 | |
Withdrawn |
NCT00600236 -
HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population
|
Phase 3 | |
Active, not recruiting |
NCT05887635 -
Study of Duodenal Mucosal RF Vapor Ablation in Subjects With Type-2 Diabetes Mellitus
|
N/A | |
Completed |
NCT03903965 -
Comparison of Retinal Perfusion Between Diabetic and Non-diabetic Patients With OCT Angiography After Cataract Surgery.
|
||
Completed |
NCT02666924 -
Cooking Classes for Chinese Canadian Patients Living With Diabetes
|
N/A | |
Recruiting |
NCT02501850 -
The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)
|
Phase 4 |